KURA news & sentiment — Kura Oncology, Inc.

APR 27·BioPharma APACMed

Kyowa Kirin Co., Ltd. And Kura Oncology, Inc. Advance Ziftomenib With Japan Phase 2 Trial In NPM1 Mutated AML

Kyowa Kirin Co., Ltd. and Kura Oncology, Inc. have initiated a Phase 2 registrational clinical trial in Japan for ziftomenib, an oral menin inhibitor aimed at treating relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). This step is crucial for potential regulatory approval in Japan, following its FDA approval in November 2025 for similar patient populations in the U.S. The trial seeks to confirm the drug's efficacy and safety, addressing a significant unmet medical need for AML patients.

APR 11·Stock Titan

[ARS] Kura Oncology, Inc. SEC Filing

This article announces an ARS SEC filing by Kura Oncology, Inc. (KURA) on April 10, 2026, at 4:45 PM. The filing has a low impact and neutral sentiment. The article also provides a brief overview of KURA's stock data, rankings, and recent news and SEC filings.

APR 8·Benzinga

Delta Air Lines, RPM International And 3 Stocks To Watch Heading Into Wednesday

As U.S. stock futures trade higher, investors are focusing on several companies ahead of Wednesday's market open. Delta Air Lines, RPM International, and Constellation Brands are set to release earnings, while Kura Sushi USA reported a narrower loss and Levi Strauss & Co. exceeded expectations and raised its full-year guidance. These companies are poised to be key movers in Wednesday's trading session.

$KURA

Kyowa Kirin Co., Ltd. And Kura Oncology, Inc. Advance Ziftomenib With Japan Phase 2 Trial In NPM1 Mutated AML

[ARS] Kura Oncology, Inc. SEC Filing

Delta Air Lines, RPM International And 3 Stocks To Watch Heading Into Wednesday

News on $KURA